Cantabio Pharmaceuticals Inc. (OTCQB: CTBO) is a biotechnology company that is currently in the preclinical stage. The company seeks to commercialize its treatments, therapies, and intellectual property as it concerns with Parkinson’s disease, Alzheimer’s disease, Dementia, and other neurodegenerative diseases. Shares of Cantabio Pharmaceuticals Inc. are declining nearly 20% during morning trading on Friday, September 2, 2016. Over the past month, the pharmaceutical company has seen average daily volume of around 44,565 shares. However, nearly 113,000 shares or dollar volume of $111,870, has already exchanged hands through early trading Friday. When taking into consideration the losses that Cantabio Pharmaceuticals Inc is facing today, the biotech company has seen shares lose over 46% in the past five trading days.

It has been over two weeks since management of Cantabio Pharmaceuticals Inc released new information or press of any kind. Anxious investors could be concerned with the lack of vision and understanding of when Cantabio Pharmaceuticals Inc will be able to get a drug approved and on the market. Taking into the consideration the headwinds the overall health care industry and drug pricing faces right now, these factors could also be pushing shares lower of the biotech company.

Fifteen days ago, management released an update detailing that the company’s DJ-1 protein targeting technology to the 4th World Parkinson’s Congress on September 20-22 and the 3rd International Parkinson’s Disease Symposium on October 6-8. Here is the press release detailing of the company’s presentations:

Cantabio Pharmaceuticals Inc Press Release:

SAN FRANCISCO, Calif., Aug. 18, 2016 (GLOBE NEWSWIRE) –Cantabio Pharmaceuticals, Inc. (CTBO), a biopharmaceutical company developing novel disease modifying therapies for Alzheimer’s, Parkinson’s (PD) and other related neurodegenerative diseases, today announced that Dr. Gergely Toth, Chief Executive Officer, will present results of the company’s DJ-1 protein targeting small molecule pharmacological chaperone therapeutic programs at two conferences: the 4th World Parkinson’s Congress in Portland, Oregon on September 20-22; and, the 3rd International Parkinson’s Disease Symposium in Luxemburg on October 6-8.

DJ-1 is one of the key proteins involved in the prevention and reduction of damage due to oxidative stress and protein misfolding in brain cells.  Loss of DJ-1 protein function has been linked to the onset and progression of familial and sporadic PD and other neurodegenerative diseases. Rescuing cells from the loss of DJ-1 function could be a critical factor in progressing towards a viable treatment of PD.

The presentations will describe the chemical microarray based high throughput binding screening applied for the identification of a diverse set of novel DJ-1 small molecule ligands, and characterization of one class of small molecule ligands and their positive biological activity in cellular and in vivo models of PD.

Key findings to be presented include that Cantabio’s novel DJ-1 targeting compound:

  • Significantly increased life span of Drosophila melanogaster treated with paraquat, an in vivo oxidative stress model;
  • Reduced neuroblastoma cell toxicity and dopaminergic neuronal loss mediated by paraquat treatment;
  • Rescued rotenone-treated neuronal differentiated mesenchymal stem cells from toxicity, reactive oxygen species accumulation, caspase-3 activation, and mitochondrial membrane potential dysfunction.

The data will be presented at:

4th World Parkinson’s Congress, Portland, Oregon, USA

September 22, 11:30 -13:30 PST – Room: Exhibit Hall B, Level 1, Poster Board Number P04.09.

A poster presentation will be delivered, titled, “Identification of novel biologically active DJ-1 small molecule modulators with activity in cellular and in vivo models of oxidative stress relevant to Parkinson’s disease”

3rd International Parkinson’s Disease Symposium, Luxemburg, Europe

October 7, 12:15 – 13:30 CET- A poster presentation will be delivered, titled, “Identification of novel biologically active DJ-1 targeting small molecule modulators with protective activity in neuron and in vivo models of oxidative stress relevant to Parkinson’s disease”

The presentations’ lead author is Cantabio Pharmaceuticals, with co-authoring by researchers at Purdue University (USA), Novalix SAS (France), University of Antioquia (Colombia), and the Hungarian Academy of Sciences and University of Szeged (Hungary).

About Cantabio Pharmaceuticals, Inc.

Cantabio is focused on bringing novel, first-in-class drug candidates into clinical trials and beyond through the discovery and development of innovative pharmacological chaperone and protein delivery based therapeutics, focusing on protein systems implicated in neurodegenerative disorders, including Alzheimer’s and Parkinson’s, and oxidative stress. The company is currently engaged in advanced pre-clinical trials of its therapeutic candidates and is focused on developing these towards clinical trials. More information is available at www.cantabio.com.

Add a Comment to this Post

comments